COVID-19 Advanced Care.
Evangelia FoukaIoannis KalomenidisNiki GianniouSofia GidaPaschalis SteiropoulosPublished in: Journal of personalized medicine (2021)
The coronavirus disease 2019 (COVID-19) pandemic, related to the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a worldwide sudden and substantial burden in public health due to an enormous increase in hospitalizations for pneumonia with the multiorgan disease. Treatment for individuals with COVID-19 includes best practices for supportive management of acute hypoxic respiratory failure. Emerging data indicate that dexamethasone therapy reduces 28-day mortality in patients requiring supplemental oxygen compared with usual care, and ongoing trials are testing the efficacy of antiviral therapies, immune modulators and anticoagulants in the prevention of disease progression and complications, while monoclonal antibodies and hyperimmune globulin may provide additional preventive strategies. Consensus suggestions can standardize care, thereby improving outcomes and facilitating future research. This review discusses current evidence regarding the pharmacotherapy of COVID-19.
Keyphrases
- coronavirus disease
- respiratory syndrome coronavirus
- sars cov
- respiratory failure
- healthcare
- public health
- palliative care
- end stage renal disease
- extracorporeal membrane oxygenation
- quality improvement
- mechanical ventilation
- primary care
- chronic kidney disease
- risk factors
- pain management
- affordable care act
- metabolic syndrome
- peritoneal dialysis
- stem cells
- prognostic factors
- cardiovascular events
- small molecule
- liver failure
- high dose
- replacement therapy
- smoking cessation
- acute respiratory distress syndrome
- big data
- artificial intelligence
- clinical practice
- intensive care unit
- cardiovascular disease
- bone marrow
- electronic health record
- machine learning
- community acquired pneumonia